Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Preparing for the Next Influenza Pandemic
Companies Invest in Array of Approaches to Accelerate Vaccine and Therapeutic Production
- Since the H1N1 strain of influenza emerged last spring, there has been a flurry of activity to find strategies to treat the strain more effectively, to make doses of existing therapeutics go further, and to develop new vaccines more quickly than possible with the traditional chicken-and-egg method still used ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.